Upfront use of gemtuzumab ozogamicin in young children with CD33-positive AML
| Autor: | Yoav Burstein, Dror Sayar, Rina Dvir, Amos Toren, Bela Bielorai |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Pediatrics
medicine.medical_specialty Gemtuzumab ozogamicin Sialic Acid Binding Ig-like Lectin 3 CD33 Antigens Differentiation Myelomonocytic Disease Antibodies Monoclonal Humanized Antigen-Antibody Reactions Blood cancer Fatal Outcome Antigens CD Recurrence Antineoplastic Combined Chemotherapy Protocols Pulmonary fibrosis medicine Humans Toddler biology business.industry Antibodies Monoclonal Infant Myeloid leukemia Hematology medicine.disease Gemtuzumab Leukemia Myeloid Acute Aminoglycosides Oncology Pediatrics Perinatology and Child Health Immunology biology.protein Female Antibody business medicine.drug |
| Zdroj: | Pediatric Blood & Cancer. |
| ISSN: | 1545-5017 1545-5009 |
| DOI: | 10.1002/pbc.22404 |
| Popis: | Gemtuzumab ozogamicin (GO) is a humanized anti-CD33 antibody used for treating patients with CD33+ acute myeloid leukemia (AML). We report three young children (two infants and one toddler) with AML treated with GO 9 mg/m2. Two received two doses at diagnosis alone with conventional chemotherapy and one received one dose after relapse. GO was well tolerated and all three achieved remission. All were transplanted: one relapsed after 5 months and died of disease, one died a toxic death in remission due to pulmonary fibrosis, and one survived (41 months from diagnosis). In conclusion, GO was well tolerated in these young patients with evidence for efficacy. Pediatr Blood Cancer 2010;55:183–185. © 2010 Wiley-Liss, Inc. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text